TRENTAL 400 Modified release tablet Ref.[7993] Active ingredients: Pentoxifylline

Source: Medicines & Healthcare Products Regulatory Agency (GB)  Revision Year: 2019  Publisher: Aventis Pharma Limited, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, UK Trading as: Sanofi, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, UK

Product name and form

TRENTAL 400.

Pharmaceutical Form

Modified release tablet.

Qualitative and quantitative composition

Pentoxifylline 400MG.

Active Ingredient Description
Pentoxifylline

Pentoxifylline has been shown to increase leukocyte deformability and to inhibit neutrophil adhesion and activation.

List of Excipients

Hydroxyethyl cellulose
Povidone
Talc
Magnesium stearate
Hypromellose
Macrogol 8000
Erythrosine (E127)
Titanium dioxide (E171)

Pack sizes and marketing

Amber glass bottle: 100 or 250 tablets.

Plastic (PE) pots: 100 or 250 tablets.

Blister Pack (Alu/PVC): 10 or 90 tablets.

Marketing authorization holder

Aventis Pharma Limited, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, UK

Trading as: Sanofi, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, UK

Marketing authorization dates and numbers

PL 04425/0213

15th April 2002

Drugs

Drug Countries
TRENTAL Austria, Germany, Ecuador, Estonia, Hong Kong, Croatia, Lithuania, Mexico, Netherlands, New Zealand, Singapore, Turkey, United Kingdom

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.